286 272

Full metadata record

DC FieldValueLanguage
dc.contributor.author박예수-
dc.date.accessioned2019-12-02T02:09:53Z-
dc.date.available2019-12-02T02:09:53Z-
dc.date.issued2017-11-
dc.identifier.citationOsteoporosis and Sarcopenia, v. 3, no. 4, page. 164-169en_US
dc.identifier.issn2405-5255-
dc.identifier.issn2405-5263-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2405525517302029?via%3Dihub-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/116203-
dc.description.abstract2.5 or less. In conclusion, we need more meticulous approach for surgical treatment of severe osteoporosis who had fragility fracture. In cases of advanced severe osteoporosis, we recommend more aggressive managements using parathyroid hormone and receptor activator of nuclear factor kappa-B ligand monoclonal antibody.en_US
dc.language.isoen_USen_US
dc.publisher대한골다공증학회en_US
dc.subjectAdvanced severe osteoporosisen_US
dc.subjectFragility fracturesen_US
dc.subjectSurgical treatmenten_US
dc.subjectSevere osteoporosisen_US
dc.titleSurgical treatment of severe osteoporosis including new concept of advanced severe osteoporosisen_US
dc.typeArticleen_US
dc.relation.no4-
dc.relation.volume3-
dc.identifier.doi10.1016/j.afos.2017.11.006-
dc.relation.page164-169-
dc.relation.journalOsteoporosis and Sarcopenia-
dc.contributor.googleauthorKim, Jin Hwan-
dc.contributor.googleauthorPark, Ye-Soo-
dc.contributor.googleauthorOh, Kwang Jun-
dc.contributor.googleauthorChoi, Han Seok-
dc.relation.code2017019835-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidhyparkys-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE